Amendment No. 04

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereoy issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

93870

Licensee

1. MPI Pharmacy Services, Inc.

2. 823 North 12th Street
Milwaukee, WI 53200

In accordance with letters dated August 12, 1992 and September 17, 1992

3 License number 48-26240-01MD is amended in its entirety to read as follows:

4. Expiration date September 30, 1995

5. Docket or Reference No 030-31890

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Molybdenum-99	A. Any Molybdenum-99/technetium-99m generator manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.73 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	A. 200 curies
B. Any byproduct material listed in paragraph 31.11(a) of 10 CFR Part 31	B. Prepackaged in vitro diagnostic test kits	B. 50 millicuries total posession limit

24010G

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-26240-01MD

Docket or Reference number
030-31890

Amendment No. 04

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
C. Any byproduct material authorized under paragraph 35.14(d)(4) of 10 CFR Part 35 (superseded) or paragraph 35.57(a) of 10 CFR Part 35 (effective April 1, 1987)	C. Any sealed source listed in paragraph 35.14(d)(4) of 10 CFR Part 35 (superseded) or paragraph 35.57(a) of 10 CFR Part 35 (effective April 1, 1987) that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.74 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	C. 50 millicuries total for all sources authorized under Subitem 6.C

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 48-26240-01MD
Docket or Reference number: 030-31890
Amendment No. 04

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
D. Xenon-133	D. Unit dose container of gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a "New Drug" (IND) that has been accepted by FDA	D. 2 curies
E. Iodine-131	E. Any form listed in Groups I through V of Schedule A, Section 35.100, of 10 CFR Part 35 (superseded) or Sections 35.100, 35.200, 35.300 of 10 CFR Part 35 (effective April 1, 1987)	E. 1000 millicuries
F. Technetium-99m	F. Any form listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Sections 35.100, and 35.200 of 10 CFR Part 35 (effective April 1, 1987)	F. 200 curies

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 48-26240-01MD

Docket or Reference number: 030-31890

Amendment No. 04

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Any byproduct material, except iodine-131 and technetium-99m, listed in group I of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.100 of 10 CFR Part 35 (effective April 1, 1987)	G. Any form listed in Group I of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.100 of 10 CFR Part 35 (effective April 1, 1987)	G. 50 millicuries total possession limit
H. Any byproduct material, except iodine-131 and technetium-99m, listed in Group II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.200 of 10 CFR Part 35 (effective April 1, 1987)	H. Any form listed in Group II of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.200 of 10 CFR Part 35 (effective April 1, 1987)	H. 200 millicuries total possession limit
I. Any byproduct material, except iodine-131, listed in Group IV of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.300 of 10 CFR Part 35 (effective April 1, 1987)	I. Any form listed in Group IV of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Section 35.300 of 10 CFR Part 35 (effective April 1, 1987)	I. 100 Millicuries total possession limit

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 48-26240-01MD

Docket or Reference number: 030-31890

Amendment No. 04

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
J. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or Sections 35.400 and 35.500 of 10 CFR Part 35 (effective April 1, 1987)	J. Any sealed source that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.74 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	J. 4 curies
K. Uranium (depleted in	K. Metal encased in the isotope Uranium 235)	K. 400 kilograms stainless steel

9. Authorized Use:

A. Production of technetium-99m pertechnetate. Redistribution of unused generators to authorized recipients in accordance with statements, representations and procedures contained in application dated April 29, 1988 and letters dated June 15, 1988 and July 15, 1988.

B. Redistribution to general and specific licensees in accordance with statements, representations and procedures contained in application dated April 29, 1988.

C. Instrument calibration. Redistribution of sources to specifically authorized recipients. Pursuant to Section 32.74 of 10 CFR Part 32, the licensee is authorized to redistribute sources to persons licensed pursuant to Sections 35.14 and 35.100 of 10 CFR Part 35 (superseded) or Section 35.57(a) of 10 CFR Part 35 (effective April 1, 1987) or under equivalent licenses of Agreement states.

D. Distribution to authorized recipients.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-26240-01MD

Docket or Reference number
030-31890

Amendment No. 04

9. (Continued)

E. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients. Compounding of iodine-131 capsules and distribution of these capsules to authorized recipients in accordance with the statements, representations and procedures contained in letters dated November 8, 1988 and December 23, 1988.

F. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients. Use of technetium-99m pertechnetate for processing with reagent kits in preparing radiopharmaceuticals.

G. through I. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients

J. Redistribution of sealed sources as received from the manufacturer in the manufacturer's original packaging and shielding and accompanied by the manufacturer's approved instructions to authorized recipients for use and storage.

K. Shielding for Mo99/Tc99m generators.

Pursuant to Sections 32.72, 32.73 and 32.74 of 10 CFR Part 32, the licensee is authorized to distribute the byproduct material described in Items 6 and 7 of this license to persons licensed pursuant to Sections 35.14 and 35.100 of 10 CFR Part 35 (superseded) or Sections 35.100, 35.200, 35.300, 35.400 and 35.500 of 10 CFR Part 35 (effective April 1, 1987), or under equivalent licenses of Agreement States, for the Groups or Sections indicated below:

A. Unused molybdenum-99/technetium-999m generators may be redistributed to persons licensed pursuant to Group III or Section 10 CFR 35.200.

D. Gas or gas in saline may be distributed to person licensed pursuant to 10 CFR 35.200 (effective April 1, 1987).

E. through I. Any form listed in each group, Groups I, II, IV and V of Schedule A, Section 35.100 of 10 CFR Part 35 (superseded) or authorized by Sections 35.100, 35.200, and 35.300 (effective April, 1987), may be distributed to persons licensed pursuant to that Group of Section.

J. Sealed sources may be redistributed to persons licensed pursuant to Group VI or Sections 35.400 and 35.500. (effective April 1, 1987).

Conditions

10. Licensed material shall be used only at the licensee's facilities located at 823 North 12th Street, Milwaukee, WI.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-26240-01MD

Docket or Reference number
030-31890

Amendment No. 04

11. Licensed material shall be used by, or under the supervision of, William Brockmeyer, Margo Hein, Robert Wells, Jimmy Coker, Ted Weyandt, Rochelle Darnell, Andrea Downey, Theresa Colangelo, Cathy Bach, Gerald Cease, Ken DeTurk, John Ellis, Ned Gregorio, Sandra Kneefel, Nori Morakawa, Lawrence Andreatta, Felix Muniz, Karl Nigg, James Pancy, Erma Peterson, Roy Storey, Woodrow Storey, Cynthia Stroebel, Michael Wakefield, Richard Gritt Robert Freissen, Brian Schultz, Timothy Strane or Mark Sharafinski.

12. At least one individual named in Condition 11. shall be physically present at the authorized place of use whenever licensed material is being used.

13. The Radiation Protection Officer for the activities authorized by this license is Robert Freissen.

14. A. (1) The source(s) specified in Item(s) 7.C and 7.J shall be tested for leakage and/or contamination at intervals not to exceed 6 months. Any source received from another person which is not accompanied by a certificate indicating that a test was performed within 6 months before the transfer shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. Any source in storage and not being used need not be tested. When the source is removed from storage for use or transfer to another person, it shall be tested before use or transfer.

C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source shall be removed from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, ATTN: Chief, Nuclear Materials Safety Branch. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

15. Sealed sources containing licensed material shall not be opened.

16. The licensee shall conduct a physical inventory every 6 months to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 2 years from the date of each inventory.

17. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

18. A. Radiopharmaceuticals dispensed and/or distributed for human use shall be either:

(i) Repackaged from prepared radiopharmaceuticals that are the subject of an FDA-approved "New Drug Application" (NDA) or for which FDA has accepted a "Notice of Claimed Investigational Exemption for a New Drug" (IND), or

(ii) Prepared from generators and reagent kits that are the subject of an FDA-approved NDA or for which FDA has accepted an IND.

B. Prepared radiopharmaceuticals for which FDA has accepted an IND and radiopharmaceuticals prepared from generators or reagent kits for which FDA has accepted an IND shall be dispensed and/or distributed:

(i) In accordance with the directions provided by the sponsor of the IND, and

(ii) Only to physicians who have been accepted by the sponsor of the IND to participate in clinical evaluation of the drug.

The licensee shall inform in writing each physician who participates in an IND evaluation that the physician is responsible to the sponsor of the IND for use of the drug in accordance with protocols established by the sponsor and for reporting to the sponsor the clinical information obtained through use of the drug.

19. The licensee shall elute generators and process radioactive material with reagent kits in accordance with instructions furnished by the manufacturer on the label attached to or in the leaflet or brochure that accompanies the generator or reagent kit.

20. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 48-26240-01MD

Docket or Reference number: 030-31890

Amendment No. 04

20. (Continued)

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

21. Any proposed changes in packaging, shielding or labelling shall be submitted for review to the U.S. Nuclear Regulatory Commission, Region III, Materials Licensing Section, 799 Roosevelt Rd., Glen Ellyn, Illinois 60137.

22. Reagent kits may be redistributed to persons licensed pursuant to Sections 35.14 and 35.100 of 10 CFR Part 35, or under equivalent licenses of Agreement States, for Group III.

23. Radioactive waste may be picked up from the licensee's customers and disposed of in accordance with the procedures, statements and representations in application dated April 29, 1988.

24. The licensee may use the Calicheck device for doing linearity tests of its dose calibrator provided it follows the procedures in the Calcorp, Inc., Manual dated March 2, 1982.

25. The licensee may use the Lineator device for doing linearity tests of its dose calibrator provided it follows the procedures in the Atomic Products Corporation Lineator Instructions Manual dated June 20, 1983.

26. The licensee shall maintain records of information important to safe and effective decommissioning at MPI Pharmacy Services, Inc., 823 North 12th Street, Milwaukee, Wisconsin per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
48-26240-01MD

Docket or Reference number
030-31890

Amendment No. 04

27. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 29, 1988;

B. Letters dated June 15, 1988, July 15, 1988, November 8, 1988, December 23, 1988, July 13, 1990, April 4, 1991, August 12, 1992 and September 17, 1992.

C. State of Wisconsin Pharmacy Examining Board Certificate received July 28, 1988.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date OCT 2 6 1992

By Lorna J. Hueter
Materials Licensing Section, Region III

COPY

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02500
STATUS CODE: 0
FEE CATEGORY: 3C
EXP. DATE: 19950930
FEE COMMENTS:
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION III

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: MPI PHARMACY SERVICES, INC.
RECEIVED DATE: 920819
DOCKET NO: 3031890
CONTROL NO.: 393870
LICENSE NO.: 48-26240-01MD
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: 490.00
CHECK NO.: 0020372

3. COMMENTS

SIGNED Deborah Harvey
DATE 9/28/92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED 10/1)

1. FEE CATEGORY AND AMOUNT: 3C - $460

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT ✓
RENEWAL
LICENSE

3. OTHER $30 Refunded

SIGNED Rita Jacque
DATE 9/28/92

RECEIVED
SEP 01 1992
REGION III

93870

NRC Form 240A
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

VOUCHER COVER SHEET

MPI PHARMACY SERVICE INC
ATTN ROBERT W FRIESSEN
RSO
823 NORTH 12TH STREET
MILWAUKEE WI 53233
EXEMPT FEE APPL DTD
8/12/92 L/C 48-26240-01MD
CHECK 02036

ACCOUNT NO: AA905 AMD CD NO: _____

FEE CATEGORY: 3C CONTROL NO: 393870

DATE RECEIVED: 8/24/92

CHECK AMOUNT: $490.00

AMOUNT RETAINED: $460.00

AMOUNT REFUNDED: $30.00

COMMENTS: _____

SIGNED: M. Mercier

DATE: 8/25/92

31X6875

GOVERNMENT CODE: Y N

DOCUMENT NUMBER	
TRANSACTION CODE	AMOUNT
B&R NUMBER	
FIN	
FEE RETAINED CODE 303	FEE PAID CODE 410
DISCOUNT (CODE 000) TAKEN	DISCOUNT (CODE 415) LOST
AMOUNT PAID $30.00	
	FINAL Y N

mpl
pharmacy services inc
an Amersham company

823 North 12th Street
Milwaukee, WI 53233
(414) 271-6763
Fax (414) 271-6817

August 12, 1992

Licensing Department
Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

RE: Radioactive Materials License No. 48-26240-01MD
Docket No. 030-31890

To whom it may concern;

On behalf of MPI Pharmacy Services, Inc., I would like to request an amendment to our letter dated November 8, 1988. Please amend the license to allow the preparation of I-131 Therapy Capsules and the dispensing of I-131 Therapy Solution with syringes and pipets.

Enclosed is a check for $490.00, to cover the cost associated with making this change.

If you have any questions, please contact me at the above listed phone number.

Sincerely,

Robert W. Friessen

Robert W. Friessen
Radiation Safety Officer

Enclosure

'92 AUG 24 P3:08
U.S. NUCLEAR REGULATORY COMMISSION

Log 0-93-15 III
Remitter
Check No. 07031/6
Amount $490.00 ($30 Refunded)
Fee Category 3C
Type of Fee Amd
Date Check Rec'd. 8/26 8/24
Date Completed 8/26
By:

Pm 8/17/92

RECEIVED
AUG 19 1992
REGION III

CONTROL NO. AUG 19 1992 93870

OCT 2 7 1992

MyI Pharmacy Services, Inc.
ATTN: Rober W. Friessen
Manager, Radiation Safety
Officer
823 North 12th Street
Milwaukee, WI 53200

Dear Mr. Friessen:

Enclosed is Amendment No. 04 to your NRC License No. 43-26240-01MD in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Possess radioactive material only in the quantity and form indicated in your license.

3. Use radioactive material only for the purpose(s) indicated in your license.

4. Notify NRC in writing of any change in mailing address.

5. Request and obtain appropriate amendment if you plan to change ownership of your o zation, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your license conditions or representations made in your license application and any supplemental correspondence with NRC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.

6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material prior to your expiration date.

93870

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations in your license application will result in enforcement action against you in accordance with the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

If you have any questions or require clarification of any of the above stated information, contact us at (708) 790-5625.

Sincerely,

Original Signed By
Loren J. Hueter
Materials Licensing Section

Enclosure: Amendment No. 04

RIII
LJH
Hueter/sd
10/26/92

mpl
pharmacy services inc
an Amersham company

823 North 12th Street
Milwaukee, WI 53233
(414) 271-6763
Fax (414) 271-8817

September 17, 1992

Loren Hueter
U.S. Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

RE: Additional Information
Control #93870

Dear Mr. Hueter,

Our current I-131 Therapy dispensing procedure was outlined in our letter dated November 8, 1988. In this letter we stated that we would dispense solution and compound capsules using a pipet method.

I would like to amend this procedure to include the use of a syringe. All effluent monitoring and bioassay procedures will remain enforce in accordance with our November 8, 1988 letter.

Enclosed, find a copy of the new procedure using a syringe.

If you have any questions, please do not hesitate to call. I appreciate your time in this matter.

Sincerely,

Robert W. Friessen

Robert W. Friessen
Manager/R.S.O.

IODINE -131 THERAPY PREPARATION PROCEDURE

All capsules will be compounded and dispensed only per the prescription of a physician authorized by NRC/Agreement State to use 131-Sodium Iodide.

SUGGESTED MATERIAL:

*No. 00 gelatin capsules
*No. 0 gelatin capsules
*Dibasic sodium phosphate anhydrous powder (U.S.P.)
*I-131 solution as Sodium Iodide
*TB syringe
*Capsule container
*Lead brick with one hole, 1/2 inch deep, approximately 1 inch in diameter
*Drawing station in iodine fume hood
*Tweezers and long forceps
*Absorbent material, plastic backed pads
*Low level survey meter

REQUIRED DOSIMETRY:

Whole body and ring badges worn properly throughout procedure

SUGGESTED SHIELDING:

1. L-block shield with a minimum of one inch of lead, located inside the iodine fume hood.
2. Capsule containers for compounded capsules.
3. Various size manufacturer's shields for packaging and shipping final product.

PACKAGING SUGGESTIONS:

- If the capsule is less than 15mCi, it may be packaged in four pound unit dose shield (1/2 inch lead thickness).
- If the capsule is 15-30mCi, it should be packaged in a larger lead container (the large CIS-US therapy capsule container, which is approximately one inch thick, is ideal).
- If greater than 30mCi, additional shielding may be required. A generator shipping shield (sleeve) can be used in conjunction with the I-131 foam inserts to reduce external/surface exposure and thereby reduce the Transport Index.

Always confirm these expectations with actual DOT measurements.

Preparation/Compounding Technique

1. Organize materials in the iodine fume hood. As per required policy, the fume hood must be on at all times with the air monitoring system functional.

2. Capsule Preparation
   Fill one 0 size capsule with dibasic sodium phosphate powder. Also fill top portion and put two halves together.

3. Place capsule in holding device inside lead block, behind the L-block in the fume hood.

4. Using a TB syringe, draw up calculated amount of Iodine and measure syringe. Allowing for 10% loss in syringe, inject through capsule wall once you have the desired amount. Enclose this capsule in a size 00 capsule for further protection.

5. Measure final capsule for accuracy.

CONVERSATION RECORD

TIME

DATE 9-14-92

TYPE ☐ VISIT ☐ CONFERENCE ☑ TELEPHONE ☐ INCOMING ☑ OUTGOING

Location of Visit/Conference:

NAME OF PERSON(S) CONTACTED OR IN CONTACT WITH YOU	ORGANIZATION (Office, dept., bureau, etc.)	TELEPHONE NO.
Robert Friesen Radiation Safety Officer	RPI Chemistry Dept Troy, NY 12180-3590	414- 271-6763

ROUTING

NAME/SYMBOL	INT

SUBJECT

CN (93870)

SUMMARY

Need to submit a separate complete procedure for preparation of I-131 therapy capsule using syringes, similar to that using pipet as described in November 8, 1985 letter.

Ref. CN 93870

Friesen said would FAX it by Thurs Sept 17 so it should arrive Fri Sept 18th

ACTION REQUIRED

NAME OF PERSON DOCUMENTING CONVERSATION	SIGNATURE	DATE
	Lorin J. Hoeter	9-14-92

ACTION TAKEN

SIGNATURE	TITLE	DATE